ClinicaliQ Trial Snapshot
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — Recruiting • Phase III • Mental Health / Psychiatry • NCT06793397.
- New psilocin-based drug CYB003 tested against placebo for treating depression as an add-on therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. Conditions: Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression Interventions: CYB003, Psychological Support Lead Sponsor: Cybin IRL Limited Planned Enrollment: 330 participants